A mixed‐methods study of cyclin‐dependent kinase 4 and 6 inhibitor symptom burden and quality of life among metastatic breast cancer patients and providers

Background Cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor targeted therapies dramatically improve survival outcomes for metastatic breast cancer (MBC), but they are associated with significant symptom burden that can impact patients’ health‐related quality of life (HRQOL) and treatment outcomes....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Cancer medicine (Malden, MA) Jg. 10; H. 14; S. 4823 - 4831
Hauptverfasser: Oswald, Laura B., Arredondo, Brandy, Kadono, Mika, Martinez‐Tyson, Dinorah, Meade, Cathy D., Penedo, Frank, Antoni, Michael H., Soliman, Hatem, Costa, Ricardo L. B., Jim, Heather S. L.
Format: Journal Article
Sprache:Englisch
Veröffentlicht: United States John Wiley & Sons, Inc 01.07.2021
John Wiley and Sons Inc
Wiley
Schlagworte:
Adult
Advanced practice nurses
Aged
Breast cancer
breast neoplasms
Breast Neoplasms - chemistry
Breast Neoplasms - drug therapy
Breast Neoplasms - pathology
Breast Neoplasms - psychology
Cancer therapies
Clinical Cancer Research
Clinical trials
Cyclin-dependent kinase 4
Cyclin-Dependent Kinase 4 - antagonists & inhibitors
Cyclin-Dependent Kinase 6 - antagonists & inhibitors
Cyclin-Dependent Kinase Inhibitor Proteins - adverse effects
Cyclin-Dependent Kinase Inhibitor Proteins - therapeutic use
Cyclin-dependent kinases
Demographics
Endocrine therapy
Enzyme inhibitors
Ethnicity
Fatigue - chemically induced
Female
Hispanic Americans
Humans
Medical prognosis
Metastases
Metastasis
Middle Aged
Mixed methods research
Molecular Targeted Therapy
Needs Assessment
neoplasm metastasis
Oncologists
Oncology
Original Research
Patient Reported Outcome Measures
Patients
patient‐reported outcomes measures
psycho‐oncology
Qualitative Research
Quality of Life
Symptom management
patient-reported outcomes measures
neoplasm metastasis
qualitative research
quality of life
breast neoplasms
psycho-oncology
ISSN:2045-7634, 2045-7634
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background Cyclin‐dependent kinase 4 and 6 (CDK4/6) inhibitor targeted therapies dramatically improve survival outcomes for metastatic breast cancer (MBC), but they are associated with significant symptom burden that can impact patients’ health‐related quality of life (HRQOL) and treatment outcomes. This study is the first to describe CDK4/6 inhibitor symptoms from the lived perspectives of MBC patients taking CDK4/6 inhibitors and healthcare providers involved in MBC care. This study also explored patients’ symptom management and HRQOL concerns, and gathered feedback about developing supportive interventions for MBC. Methods MBC patients taking CDK4/6 inhibitors (N = 20) and MBC healthcare providers (N = 12) participated in semi‐structured interviews that were analyzed for qualitative themes. MBC patients completed surveys about HRQOL, symptoms, and unmet needs. Results Patient and provider perceptions of CDK4/6 inhibitor symptoms did not align with patients perceiving symptoms as more burdensome. Patients reported that supportive resources (e.g., support groups, blogs) that are not specific to MBC do not adequately meet their needs. Patients and providers were enthusiastic about developing supportive interventions specifically for MBC and offered considerations for designing such interventions. Conclusions Findings highlight differences in perceptions of CDK4/6 inhibitor symptom burden between MBC patients and providers. Results will inform the development of supportive interventions to assist MBC patients in managing CDK4/6 inhibitor symptom burden and maintaining HRQOL. Such interventions could also improve treatment outcomes. Metastatic breast cancer (MBC) patient and provider perceptions of symptoms associated with CDK4/6 inhibitor did not align, with patients perceiving symptoms as more burdensome. Patients reported that supportive resources (e.g., support groups, blogs) that are not specific to MBC do not adequately meet their needs, however patients and providers were enthusiastic about developing supportive interventions specifically for MBC and offered considerations for designing such interventions. Results will inform the development of supportive interventions to assist MBC patients in managing CDK4/6 inhibitor symptom burden and maintaining health‐related quality of life.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ISSN:2045-7634
2045-7634
DOI:10.1002/cam4.4055